Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States.

被引：0
|
作者：
Nadler, Eric S.
Sail, Kavita Rohidas
Chen, Lei
Thompson, Stephen F.
Kolodziej, Michael A.
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] McKesson Specialty Hlth, The Woodlands, TX USA
[3] Sanofi Aventis, Bridgewater, NJ USA
[4] US Oncol, New York Hematol Oncol, Albany, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.547
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
547
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Utilization of imaging and outcomes of care among metastatic colorectal cancer (mCRC) patients (pts) receiving bevacizumab containing regimens.
    Barzi, Afsaneh
    Zheng, Hanke
    McCombs, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Survival Outcomes With Use of Bevacizumab Beyond Progression (BBP) in Metastatic Colorectal Cancer (MCRC) Patients (Pts)
    Cartwright, T.
    Yu, E.
    Yim, Y.
    Hartnett, H.
    Chung, H.
    Halm, M.
    Forsyth, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S437 - S437
  • [3] The Role of Bevacizumab (B) in the Maintenance Treatment After Chemotherapy (CT) for Metastatic Colorectal Cancer (mCRC) Patients (pts) - an Italian Multicenter Retrospective Analysis
    Moscetti, L.
    Fabbri, A.
    Pochesci, A.
    Alesini, D.
    Gemma, D.
    Grande, R.
    Pavese, I.
    Sperduti, I.
    Franco, D.
    Ruggeri, E. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S429 - S429
  • [4] Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States.
    Gbolahan, Olumide B.
    Outlaw, Darryl Alan
    Hashemi, Neda
    Paluri, Ravi Kumar
    Williams, Grant Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)
    Sugrue, M. M.
    Purdie, D. M.
    Feng, S.
    Flynn, P. J.
    Grothey, A.
    Sargent, D. J.
    Berlin, J. D.
    Kabbinavar, F. F.
    Dong, W.
    Kozloff, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study
    Kozloff, M. F.
    Sugrue, M. M.
    Purdie, D. M.
    Berlin, J. D.
    Flynn, P. J.
    Kabbinavar, F. F.
    Sargent, D. J.
    Dong, W.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).
    Kotaka, Masahito
    Ikeda, Husao
    Ikumoto, Taro
    Tsuzie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Goto, Saori
    Itami, Atsushi
    Kato, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study
    Kozloff, Mark F.
    Berlin, Jordan
    Flynn, Patrick J.
    Kabbinavar, Fairooz
    Ashby, Mark
    Dong, Wei
    Sing, Amy P.
    Grothey, Axel
    ONCOLOGY, 2010, 78 (5-6) : 329 - 339
  • [9] CLINICAL OUTCOMES OF BEVACIZUMAB USED IN COMMUNITY ONCOLOGY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WITH CONFIRMED KRAS-STATUS
    Cartwright, Thomas
    Yim, Yeun Mi
    Yu, Elaine
    Rahul, Dhanda
    Tseng, Wan-Yu
    Forsyth, Michael
    Lopez, William
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [10] Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States.
    Lowe, Kimberly
    Garawin, Tamer
    Kelsh, Michael Anthony
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345